CYTOMX THERAPEUTICS INC
NASDAQ: CTMX (CytomX Therapeutics, Inc.)
Last update: 23 minutes ago2.02
-0.02 (-1.23%)
| Previous Close | 2.04 |
| Volume | 693,367 |
| Price / Sales | 28.42 |
| Price / Book | 1.55 |
| 52 Weeks Range |
| Profit Margin | 28.19% |
| Operating Margin (TTM) | 44.43% |
| Diluted EPS (TTM) | 0.480 |
| Quarterly Revenue Growth (YOY) | 22.80% |
| Quarterly Earnings Growth (YOY) | 70.60% |
| Total Debt/Equity (MRQ) | 32.53% |
| Current Ratio (MRQ) | 1.73 |
| Operating Cash Flow (TTM) | -81.23 M |
| Levered Free Cash Flow (TTM) | -53.07 M |
| Return on Assets (TTM) | 15.87% |
News Mood
AIStockmoo Score
| Value 30% | 3.4 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Priced low for its earnings growth. info | |
| Implied Growth info | NA |
| Valuation History info | NA |
| Low debt. Strong profitability. Ample short-term liquidity. Negative cash flow. info | |
| Return on Capital info | NA |
| Timing 30% | -4.0 |
| From our AI technical analysis of the chart. info | NA |
| Downtrend over the past year. Far below its 52-week high. info | |
| Candle Patterns info | NA |
| Trend for Your Holding Period info | NA |
| Sentiment 20% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mixed or neutral. info | |
| Smart Money 20% | -0.7 |
| Insider Activity info | NA |
| Institutions net -0.08% of shares in their latest 13F filings: 114 holders increased, 75 decreased (quarter to 30 Sep 2026). info | |
| Short interest +35.0% from 31 Aug to 30 Oct 2026, 12 days to cover (FINRA). info | |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars disagree, so the score is softened. | |
| Not in score | |
| Price is low against its 52-week average. Down over 5 years. info | |
| Trend down on all three terms. Short-term momentum falling. info | |
| Price is between support and resistance. Levels trending up. info | |
| Final Score | -0.30 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | CytomX Therapeutics, Inc. | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| CTMX | - | - | - | 1.55 |
| OPT | 583 M | - | - | 4.31 |
| OCUP | 51 M | - | - | 0.870 |
| ZYME | - | - | - | 7.29 |
| PBYI | - | - | - | 2.73 |
| ORMP | - | 6.74% | - | 0.530 |
Select this tab to load the latest available analysis.
|
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.83% |
| % Held by Institutions | 47.10% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Elmind Capital, Lp | 30 Jun 2026 | 4,550,000 |
No data within this time range.
Institutions
Institutional ownership: 103.35%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 114 | 29,761,343 |
| Decreased | 75 | 28,757,015 |
| New | 46 | 5,112,628 |
| Sold out | 32 | 6,286,727 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 45,246,966 | 12.0 |
| 15 Oct 2026 | 42,790,446 | 13.8 |
| 30 Sep 2026 | 40,813,393 | 8.7 |
| 15 Sep 2026 | 38,639,220 | 9.3 |
| 31 Aug 2026 | 33,512,293 | 11.8 |
| 14 Aug 2026 | 34,619,999 | 15.9 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 06 Nov 2026 | Yahoo Finance |
CytomX (CTMX) Q3 2026 Earnings Call Transcript
Lower diarrhea rates emerge, but toxicity control remains the key test. |
| 05 Nov 2026 | Yahoo Finance |
CytomX Therapeutics Q3 Earnings Call Highlights
CytomX Therapeutics (NASDAQ:CTMX) plans to provide a January update on its lead cancer drug candidate, Varseta-M, as it prepares for a potential registrational study in metastatic colorectal cancer in the first half of 2027. The update is expected to include the first look at overall survival data… |
| 05 Nov 2026 | Yahoo Finance |
CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 0.00% and -59.68%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 05 Nov 2026 | Yahoo Finance |
CytomX Therapeutics: Q3 Earnings Snapshot
(AP) — SOUTH SAN FRANCISCO, Calif. (AP) — CytomX Therapeutics Inc. |
| 05 Nov 2026 | Yahoo Finance |
CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update
- Varsetatug masetecan (Varseta-M) granted FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer - - Phase 1 monotherapy data update in metastatic colorectal cancer (mCRC) expected in January 2027 - - Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase… |
| 02 Nov 2026 | Yahoo Finance |
CytomX Therapeutics to Present at Upcoming November Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in November. Guggenheim 3rd Annual… |
| 29 Oct 2026 | Yahoo Finance |
CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 5, 2026, after the close of U.S.… |
| 01 Sep 2026 | Yahoo Finance |
CytomX Therapeutics to Present at Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September. Wells Fargo 21st Annual… |
| 27 Aug 2026 | Yahoo Finance |
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in 1H 2027 - SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc.… |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |